Home > Newsletters > Drug Industry Daily > Citing Unmet Need, FDA Advisers Urge Approval of Abbott’s Humira for Ulcerative Colitis
Drug Industry Daily
Aug. 29, 2012 | Vol. 11 No. 170
Citing Unmet Need, FDA Advisers Urge Approval of Abbott’s Humira for Ulcerative Colitis
Despite “fragile” trial data, the FDA should approve Abbott Laboratories’ proposed new indication for its blockbuster Humira to treat ulcerative colitis (UC) because new therapies for the chronic condition are needed and clinicians are comfortable with the drug’s safety profile, agency advisers say.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.